Assessment of recombinant adenoviral vectors for hepatic gene therapy.
about
Targeted DNA mutagenesis for the cure of chronic viral infectionsEfficient in vivo knock-down of estrogen receptor alpha: application of recombinant adenovirus vectors for delivery of short hairpin RNA.Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In VivoInduced pluripotent stem cells generated without viral integrationA20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis.Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicityCombined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.In vivo stable transduction of humanized liver tissue in chimeric mice via high-capacity adenovirus-lentivirus hybrid vector.Hepatic gene transfer as a means of tolerance induction to transgene productsIn vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.Strategies for molecular intervention in esophageal cancers and their precursor lesions.Efficient gene transfer into human hepatocytes by baculovirus vectorsRegulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.Transient disruption of intercellular junctions enables baculovirus entry into nondividing hepatocytes.Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier.In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene.Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo.Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.Delivery of novel macromolecular drugs against HIV-1.Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expressionRetargeting adenoviral vectors to improve gene transfer into tumorsNoninvasive assessment of gene transfer and expression by in vivo functional and morphologic imaging in a rabbit tumor modelLiver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction.Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapyDevelopment of viral vectors for use in cardiovascular gene therapy.Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidaseApolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectorsTransient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissuesBiology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.Liver gene therapy: advances and hurdles.Peptide targeting of adenoviral vectors to augment tumor gene transferDisrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.Disruption of the c/ebp alpha gene in adult mouse liver.
P2860
Q24620150-8469EE43-B8AB-4C5A-99B9-76D8F1BCCCE1Q25257503-B55EAA16-EE34-4E3D-8044-A53615F3D995Q28534124-16795DB9-85A7-430B-9845-8709D588577AQ29614343-9A3A24C3-C30D-445F-BB74-EF621F6CBF10Q33183441-0C21FCCF-105C-4113-B6C6-BA38ED150CBDQ33364523-003B40E8-2528-4D5C-9870-9287CF7A02FAQ33490137-E31D48DF-2BCC-4D1B-8B33-3DD5E39B2FB9Q33659517-0D3433E6-9AAE-4CBB-8582-D7CE63B4DE19Q33691863-14826905-D428-4A83-A957-0FD70236E9DDQ33775537-D4674A9C-AEEC-4021-BC04-19E408E17AFBQ33782356-58BC0F67-7076-4643-AF7E-6080CED992E2Q33802664-2F253ECA-E898-4142-BC6C-D06443068776Q33815320-8E0A3375-36A1-47AC-B118-5E009F141DAFQ33818166-E6CBC5F2-D4D9-4C88-BC7D-DBAF3647144BQ33819873-690F13F0-2A09-409C-8202-D594791B3F7DQ33846927-887FA07C-77FF-44A9-A9BB-94D25EB8C1C2Q33851759-3DA53695-F1AE-4857-B7A7-249A6CB3349EQ34202163-730BF8CC-CA73-4954-A2B4-1E7F5BBC6649Q34203283-763658F4-27B2-47E1-B8C9-CB7884D37D5EQ34209742-8C111363-93F6-4FE0-9F0B-B41F1256855FQ34365087-82385097-AEE6-4356-94A8-E957C5E5C707Q34452681-9A02C0A3-656C-4895-848E-1B9F1805838AQ34615481-8590C156-95C0-446C-90FD-4DE183EB8632Q34699410-1326ED3B-828D-492E-A636-7B2B83B47C62Q34769352-116BF340-E033-43A0-A70D-02279E37C097Q35051812-D20529E2-D956-4FBA-A716-B72DBE9C1866Q35058696-85296032-BE3F-41F2-923B-F98A793DADB8Q35109095-202C2FC5-9053-4C36-A793-65D90CB9EECAQ35232341-DFB5BAC6-4A9D-43D1-9C14-75D0943AFCECQ35260617-BF0EDD0D-787A-4F8A-8AE5-CD96B574208BQ35586463-F8390A2B-E62A-4C9C-B725-775DF71F7669Q35763533-4FF96B45-CB73-4C73-9C49-51F48E265057Q35868592-7DB19103-E693-4915-934F-E007DC1F8FC7Q35874183-4CD82FF5-D4E5-4A1A-A63B-6CB249F6D8C0Q35874197-9461349F-1B0E-4570-BE11-EBC4712194C8Q35899034-105718A1-AE43-4CBA-96B1-65A1ED6EBD80Q35904443-347B844E-38DD-49ED-999C-B97D318CA748Q36049440-4E41EFF7-5AE3-4084-9AAB-F4BE122AEBFAQ36562614-D706C6FB-88B4-45FE-A3FE-5FBAA41EB1C3Q36573179-088C4B45-C312-4788-85D3-EAF92D1BB274
P2860
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@en
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@nl
type
label
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@en
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@nl
prefLabel
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@en
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@nl
P2093
P356
P1433
P1476
Assessment of recombinant adenoviral vectors for hepatic gene therapy.
@en
P2093
Finegold M
Stratford-Perricaudet LD
P304
P356
10.1089/HUM.1993.4.4-403
P577
1993-08-01T00:00:00Z